IFI35 and myeloid sarcoma: In fact, IFP35 reflects the stimulation of type I IFN via the JAK-STAT cascade, resulting in an antiviral and antiproliferative effect in the case of endogenous secretion, and an anti-inflammatory one in the case of exogenous administration, as a DMT in MS.